TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

What is the purpose of this trial?

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

Participation Guidelines

Ages: 18 years and younger

Gender: Male only

Click here for detailed information about who can participate in this trial

Clovis Oncology, Inc.

Start Date: 11/17/2017

End Date: 10/31/2019

Last Updated: 02/22/2018

Study HIC#: 2000020433

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367
matthew.piscatelli@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Daniel P. Petrylak Headshot
Daniel P. Petrylak

Principal Investigator

Sub-Investigators